Neoadjuvant and Adjuvant Targeted Treatment in NSCLC With BRAF V600 or MET Exon 14 Mutations

Conditions: NSCLC; BRAF V600 Mutation; MET Exon 14 Mutation Interventions: Drug: Dabrafenib + Trametinib; Drug: Capmatinib Sponsors: Sun Yat-sen University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials